1 / 11

Baseline Characteristics of the Patients* - Part I

Baseline Characteristics of the Patients* - Part I. The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]. Baseline Characteristics of the Patients* - Part II. The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31].

dfaust
Download Presentation

Baseline Characteristics of the Patients* - Part I

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

  2. Baseline Characteristics of the Patients* - Part II The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

  3. Discontinuation of Study Medications and Selected Reasons for Permanent Discontinuation* The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

  4. Kaplan-Meier Curves for the Primary Outcome in the Three Study GroupsThe composite primary outcome was death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

  5. Relative Risk of the Primary Outcome and of the Main Secondary Outcome The primary composite outcome was death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure. The main secondary outcome was death from cardiovascular causes, myocardial infarction, or stroke, which was used as the primary outcome in the Heart Outcomes Prevention Evaluation (HOPE) trial. The P value is for the comparison with the noninferiority margins The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

  6. Incidence of the Primary Outcome, Its Components, and Death from Any Cause The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

  7. Secondary and Other Outcomes The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

  8. Relative Risks in Prespecified SubgroupsComparisons between the telmisartan and the ramipril group (The risk score from the Heart Outcomes Prevention Evaluation (HOPE) trial ranges from 2.350 to 5.928, with higher scores indicating higher risk. The sizes of the squares are proportioned to the numbers of events The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

  9. Relative Risks in Prespecified SubgroupsComparisons between the combination-therapy (telmisartan plus ramipril) group and the ramipril group(The risk score from the Heart Outcomes Prevention Evaluation (HOPE) trial ranges from 2.350 to 5.928, with higher scores indicating higher risk. The sizes of the squares are proportioned to the numbers of events The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

  10. Patient Eligibility Criteria - Inclusion criteria The ONTARGET Investigators. NEJM 2008 Supplementary Appendix

  11. Patient Eligibility Criteria – Exclusion criteria The ONTARGET Investigators. NEJM 2008 Supplementary Appendix

More Related